The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kriger A.G.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Kochatkov A.V.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Gorin D.S.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Lebedeva A.N.

Otdelenie khirurgii sosudov Instituta khirurgii im. A.V. Vishnevskogo, Moskva

Endocrine pancreatic tumors by type I syndrome of multiple endocrine neoplasia

Authors:

Kriger A.G., Kochatkov A.V., Gorin D.S., Lebedeva A.N.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2010;(8): 69‑75

Views: 804

Downloaded: 7

Download PDF (RU)
Contact the author
Table of contents

ENDOCRINE PANCREATIC TUMORS BY TYPE I SYNDROME OF MULTIPLE ENDOCRINE NEOPLASIA
ENDOCRINE PANCREATIC TUMORS BY TYPE I SYNDROME OF MULTIPLE ENDOCRINE NEOPLASIA

To cite this article:

Kriger AG, Kochatkov AV, Gorin DS, Lebedeva AN. Endocrine pancreatic tumors by type I syndrome of multiple endocrine neoplasia. Pirogov Russian Journal of Surgery. 2010;(8):69‑75. (In Russ.)

Подписка 2025-2 (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Close metadata
Recommended articles:
Synchronous primary multiple cancer: distal cholangiocarcinoma of the intrapancreatic common bile duct and intraductal papi­llary muci­nous tumor asso­ciated with ductal adenocarcinoma of the pancreatic tail. Piro­gov Russian Journal of Surgery. 2024;(8):57-63
Robo­tic enucleation of pancreatic insu­linoma. Piro­gov Russian Journal of Surgery. 2024;(8):64-68
Mini­mally inva­sive surgical treatment of acute necrotic collections without a progressive exudative component in patients with puru­lent-necrotic para­pancreatitis. Endo­scopic Surgery. 2024;(2):12-18
Solid pseudopapillary tumor of the pancreas. P.A. Herzen Journal of Onco­logy. 2024;(5):50-53

Keywords:

endocrine pancreatic tumors
endocrine neoplasia

Authors:

Kriger A.G.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Kochatkov A.V.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Gorin D.S.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Lebedeva A.N.

Otdelenie khirurgii sosudov Instituta khirurgii im. A.V. Vishnevskogo, Moskva

List of references:

  1. Agarwal S.K., Kennedy P.A., Scacheri P.C. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res 2005; 37: 369-374.
  2. Akerstrom G., Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 87-109.
  3. Alexander H.R., Fraker D.L., Norton J.A. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228: 228-238.
  4. Ambrosini V., Tomassetti P., Rubello D. Role of 18Fdopa PET/CT imaging in the management of patients with 111 In-pentetreotide negative GEP tumours. Nucl Med Commun 2007; 28: 473-477.
  5. Anlauf M., Garbrecht N., Henopp T. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 2006; 12: 5440-5446.
  6. Anlauf M., Perren A., Meyer C.L. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology 2005; 128: 1187-1198.
  7. Anlauf M., Schlenger R., Perren A. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 2006; 30: 560-574.
  8. Asgharian B., Chen Y.J., Patronas N.J. Meningiomas may be a component tumor of MEN1. Clin Cancer Res 2004; 10: 869-880.
  9. Balogh K., Racz K., Patocs A. Menin and its interacting proteins: elucidation of menin function. Trends Endocrinol Metab 2006; 17: 357-364.
  10. Bartsch D.K., Fendrich V., Langer P. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2005; 242: 757-764.
  11. Bartsch D.K., Langer P., Rothmund M. Surgical aspects of gastrinoma in multiple endocrine neoplasia type 1. Wien Klin Wochenschr 2007; 119: 602-608.
  12. Bartsch D.K., Langer P., Wild A. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery 2000; 128: 958-966.
  13. Beghelli S., Pelosi G., Zamboni G. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. J Pathol 1998; 186: 41-50.
  14. Benya R.V., Metz D.C., Venzon D.J. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med 1994; 97: 436-444.
  15. Bertherat J., Tenenbaum F., Perlemoine K. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 2003; 88: 5353-5360.
  16. Busygina V., Bale A.E. Multiple endocrine neoplasia type 1(MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN 1-related carcinogenesis. Yale J Biol Med 2006; 79: 105-114.
  17. Cadiot G., Bonnaud G., Lebtahi R. Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Gut 1997; 41: 107-114.
  18. Cadiot G., Houillier P., Allouch A. Oral calcium tolerance test in the early diagnosis of primary hyperparathyroidism and multiple endocrine neoplasia type 1 in patients with the Zollinger-Ellison syndrome. Groupe de Recherche et d’Etude du Syndrome de Zollinger-Ellison. Gut 1996; 39: 273-278.
  19. Cadiot G., Lebtahi R., Sarda L. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 1996; 111: 845-854.
  20. Cadiot G., Vuagnat A., Doukhan I. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Gastroenterology 1999; 116: 286-293.
  21. Chandrasekharappa S.C., Guru S.C., Manickam P. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404-407.
  22. Cougard P., Goudet P., Peix J.L. Insulinomas in multiple endocrine neoplasia type 1. Report of a series of 44 cases by the Multiple Endocrine Neoplasia Study Group [in French]. Ann Chir 2000; 125: 118-123.
  23. Crabtree J.S., Scacheri P.C., Ward J.M. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci USA 2001; 30 : 98: 3: 1118-1123.
  24. Debelenko L.V., Zhuang Z.P., Emmert-Buck M.R. Allelic deletions on chromosome 1lql3 in multiple endocrine neoplasia type-I-associated sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 1997; 57: 2238-2243.
  25. DeLellis R.A., Lloyd R.V., Heitz P.U. Eng C. Pathology And Genetics of Tumours of Endocrine Organs IARCPress, Lyon 2004; 263.
  26. Demeure M.J., Klonoff D.C., Karam J.H. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery 1991; 110: 998-1005.
  27. Dreijerink K.M., Hoppener J.W., Timmers H.M. Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation. Nat Clin Pract Endocrinol Metab 2006; 2: 562-570.
  28. Duerr E.M., Chung D.C. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007; 21: 1-14.
  29. Eriksson B., Orlefors H., Oberg K. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 311-324.
  30. Gauger P.G., Scheiman J.M., Wamsteker E.J. Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg 2003; 90: 748-754.
  31. Gibril F., Chen Y.-J., Schrump D.S. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003; 88: 1066-1081.
  32. Gibril F., Doppman J.L., Reynolds J.C. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol 1998; 16: 1040-1053.
  33. Gibril F., Jensen R.T. Diagnostic uses of radiolabeled somatostatin- receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 2004; 36: 106-120.
  34. Gibril F., Reynolds J.C., Chen C.C. Specificity of somatostatin receptor scintigraphy: a prospective study and the effects of false positive localizations on management in patients with gastrinomas. J Nucl Med 1999; 40: 539-553.
  35. Gibril F., Reynolds J.C., Doppman J.L. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 996; 125: 26-34.
  36. Gibril F., Reynolds J.C., Roy P.K. Ability of somatostatin receptor scintigraphy to identify patients with localized gastric carcinoids: a prospective study. J Nucl Med 2000; 41: 1646-1656.
  37. Gibril F., Schumann M., Pace A. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. A prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine (Baltimore) 2004; 83: 43-83.
  38. Giraud S., Zhang C.X., Serova-Sinilnikova O. Germline mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am J Hum Genet 1998; 63: 455-467.
  39. Goebel S.U., Heppner C., Burns A.D. Geneotype/phenotype correlations of MEN 1 gene mutations in sporadic gastrinoma. J Clin Endocrinol Metab 2000; 85: 116-123.
  40. Goudet P., Peschaud F., Mignon M. Les gastronomes dans les neoplasies endocriniennes multiples de type 1. Une etude de cohorte de 127 cas du Groupe des Tumeurs Endocrines (GTE). Ann Chir 2004; 129: 149-155.
  41. Grama D., Eriksson B., Martensson H. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 1992; 16: 632-639.
  42. Hellman P., Hennings J., Akerstrom G. Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1. Br J Surg 2005; 92: 1508-1512.
  43. Hillel P.G., van Beek E.J., Taylor C. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol 2006; 61: 579-587.
  44. Hoffmann K.M., Furukawa M., Jensen R.T. Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 2005; 19: 675-697.
  45. Jadoul M., Koppeschaar N.R., Bax M.A. Insulinomas in MEN-I patients: early detection and treatment of insulinomas in patients with the multiple endocrine neoplasia syndrome type-I. Neth J Med 1990; 37: 95-102.
  46. Jensen R.T., Doppman J.L., Gardner J.D. Gastrinoma. In: Go V.L.W., Brooks F.A., DiMagno E.P., Gardner J.D., Lebenthal E., Scheele G.A, eds. The Exocrine Pancreas: Biology, Pathobiology and Disease. 1st ed. New York, NY: Raven Press 1986; 727-744.
  47. Jensen R.T. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 477-488.
  48. Jensen R.T. Peptide therapy. Recent advances in the use of somatostatin and other peptide receptor agonists and antagonists. In: Lewis J.H., Dubois A., eds. Current Clinical Topics in Gastrointestinal Pharmacology. Malden, Mass: Blackwell Science, Inc 1997; 144-223.
  49. Kaltsas G.A., Besser G.M., Grossman A.B. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511.
  50. Kann P.H., Balakina E., Ivan D. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 2006; 13: 1195-1202.
  51. Kann P.H., Kann B., Fassbender W.J. Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imaging. Exp Clin Endocrinol Diabetes 2006; 114: 361-365.
  52. Karnik S.K., Chen H., McLean G.W. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science 2007; 318: 806-809.
  53. Karnik S.K., Hughes C.M., Gu X. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kipl and p18INK4c. Proc Natl Acad Sci USA 2005; 102: 14659-14664.
  54. Kauhanen S., Seppanen M., Minn H. Fluorine-18-Ldihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or betacell hyperplasia in adult patients. J Clin Endocrinol Metab 2007; 92: 1237-1244.
  55. Kloppel G., Willemar S., Stamm B. Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I. An immunocytochemical study of 9 patients. Cancer 1986; 57: 1824-1832.
  56. Kouvaraki M.A., Shapiro S.E., Cote G.J. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006; 30: 643-653.
  57. Krausz Y., Keidar Z., Kogan I. SPECT/CT hybrid imaging with 111 In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003; 59: 565-573.
  58. Krenning E.P., Kwekkeboom D.J., Bakker W.H. Somatostatin receptor scintigraphy with [11 lln-DTPA-D-Phel]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur JNucl Med 1993; 20: 716-731.
  59. Langer P., Kann P.H., Fendrich V. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg 2004; 28: 1317-1322.
  60. Larsson C., Skogseid B., Oberg K. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85-87.
  61. LeBodic M.F., Heymann M.F., Lecomte M. Immunohistochemical study of 100 pancreatic tumors in 28 patients with multiple endocrine neoplasia, type 1. Am J Surg Pathol 1996; 20: 1378-1384.
  62. Lebtahi R., Cadiot G., Delahaye N. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999; 40: 1602-1608.
  63. Lemos M.Q., Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008; 29: 22-32.
  64. Levy-Bohbot N., Merle C., Goudet P. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 2004; 28: 1075-1081.
  65. MacFarlane M.P., Fraker D.L., Alexander H.R. A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia-type 1. Surgery 1995; 118: 973-980.
  66. Machens A., Schaaf L., Karges W. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf) 2007; 67: 613-622.
  67. Marx S., Spiegel A.M., Skarulis M.C. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998; 129: 484-494.
  68. McCallum R.W., Parameswaran V., Burgess J.R. Multiple endocrine neoplasia type 1 (MEN 1) is associated with an increased prevalence of diabetes mellitus and impaired fasting glucose. Clin Endocrinol (Oxf) 2006; 65: 163-168.
  69. McLean A.M., Fairclough P.D. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 177-193.
  70. Norton J.A., Alexander H.R., Fraker D.L. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001; 234: 495-506.
  71. Norton J.A., Alexander H.R., Fraker D.L. Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg 2004; 239: 617-626.
  72. Norton J.A., Doppman J.L., Jensen R.T. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg 1992; 215: 8-18.
  73. Norton J.A., Fang T.D., Jensen R.T. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw 2006; 4: 148-153.
  74. Norton J.A., Fraker D.L., Alexander H.R. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-644.
  75. Norton J.A., Jensen R.T. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 757-773.
  76. Norton J.A., Jensen R.T. Unresolved surgical issues in the management of patients with the Zollinger-Ellison syndrome. World J Surg 1991; 15: 151-159.
  77. Norton J.A., Melcher M.L., Gibril F. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgery. Surgery 2004; 136: 1267-1274.
  78. Norton J.A. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol 2005; 19: 577-583.
  79. O’Riordain D.S., O’Brien T., Van Heerden J.A. Surgical management of insulinoma associated with multiple endocrine neoplasia type 1. World J Surg 1994; 18: 488-493.
  80. Orbuch M., Doppman J.L., Strader D.B. Imaging for pancreatic endocrine tumor localization: recent advances. In: Mignon M., Jensen R.T., eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Frontiers of Gastrointestinal Research. Basel, Switzerland: S. Karger 1995; 23: 268-281.
  81. Orlefors H., Sundin A., Garske U. Whole-body S-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90: 3392-3400.
  82. Perren A., Anlauf M., Henopp T. Multiple endocrine neoplasia type 1 (MEN1): loss of 1 MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab 2007; 92: 1118-1128.
  83. Phan G.Q., Yeo C.J., Cameron J.L. Pancreaticoduodenectomy for selected periampullary neuroendocrine tumors: fifty patients. Surgery 1997; 122: 989-997.
  84. Pipeleers-Marichal M., Somers G., Willems G. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990; 322: 723-727.
  85. Pisegna J.R., Doppman J.L., Norton J.A. Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38: 1318-1328.
  86. Rasbach D.A., van Heerden J.A., Telander R.L. Surgical management of hyperinsulinism in the multiple endocrine neoplasia, type 1 syndrome. Arch Surg 1985; 120: 584-589.
  87. Roy P., Venzon D.J., Shojamanesh H. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79: 379-411.
  88. Ruszniewski P., Amouyal P., Amouyal G. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995; 117: 629-635.
  89. Ruszniewski P., Podevin P., Cadiot G. Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas 1993; 8: 295-304.
  90. Sa S.V., Correa-Giannella M.L., Machado M.C. Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer 2006; 13: 69-78.
  91. Samaan N.A., Ouais S., Ordonez N.G. Multiple endocrine syndrome type I. Cancer 1989; 64: 741-752.
  92. Schillaci O., Spanu A., Scopinaro F. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2003; 44: 359-368.
  93. Schillaci O., Spanu A., Scopinaro F. Somatostatin receptor scintigraphy with 111 In-pentetreotide in nonfunctioning gastroenteropancreatic neuroendocrine tumors. Int J Oncol 2003; 23: 1687-1695.
  94. Schnepp R.W., Chen Y.X., Wang H. Mutation of tumor suppressor gene Menl acutely enhances proliferation of pancreatic islet cells. Cancer Res 2006; 66: 5707-5715.
  95. Shepherd J.J. The natural history of multiple endocrine neoplasia type I. Highly uncommon or highly unrecognized. Arch Surg 1991; 126: 935-952.
  96. Skogseid B., Ericksson B., Lundqvist G. Multiple endocrine neoplasia type I: a 10-year prospective screening study in 4 kindreds. J Clin Endocrinol Metab 1991; 73: 281-287.
  97. Skogseid B., Oberg K., Akerstrom G. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization? World J Surg 1998; 22: 673-678.
  98. Skogseid V., Oberg K., Eriksson B. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type 1. World J Surg 1996; 20: 872-877.
  99. Stadil F. Treatment of gastrinomas with pancreaticoduodenectomy. In: Mignon M., Jensen R.T., eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers in Gastrointestinal Research. Basel, Switzerland: S. Karger 1995; 23: 333-341.
  100. Stefanini P., Carboni M., Patrassi N. Beta-islet cell tumors of the pancreas: results of a study on 1067 cases. Surgery 1974; 75: 597-609.
  101. Termanini B., Gibril F., Reynolds J.C. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112: 335-347.
  102. Terris B., Scoazeck J.Y., Rubbia L. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32: 133-138.
  103. Teunissen J.J., Kwekkeboom D.J., de Jong M. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005; 19: 595-616.
  104. Thakker R.V. Multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am 2000; 29: 541-567.
  105. Thomas-Marques L., Murat A., Delemer B. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006; 101: 266-273.
  106. Thompson N.W., Lloyd R.V., Nishiyama R.H. MEN I pancreas: a histological and immunohistochemical study. World J Surg 1984; 8: 561-574.
  107. Thompson N.W., Pasieka J., Fukuuchi A. Duodenal gastrinomas, duodenotomy, and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J Surg 1993; 17: 455-462.
  108. Thompson N.W. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreaticduodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998; 243: 495-500.
  109. Thompson N.W. Multiple endocrine neoplasia type I. Surgical therapy. Cancer Treat Res 1997; 89: 407-419.
  110. Triponez F., Cadiot G. Nonfunctioning tumours of the pancreas in MEN1 patients. J Gastrointestin Liver Dis 2007; 16: 295-296.
  111. Triponez F., Dosseh D., Goudet P. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006; 243: 265-272.
  112. Triponez F., Goudet P., Dosseh D. Is surgery beneficial for MEN1 patients with small (
  113. Trump D., Farren B., Wooding C. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 1996; 89: 957-958.
  114. Van Essen M., Krenning E.P., de Jong M. Peptide receptor radionuclide therapy with radiolabeled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007; 46: 723-734.
  115. Vasen H.F., Lamers C.B., Lips C.J. Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in the Netherlands. Arch Intern Med 1989; 149: 2717-2722.
  116. Vilar E., Salazar R., Perez-Garcia J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007; 14: 221-232.
  117. Virgolini I., Traub-Weidinger T., Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab 2005; 19: 213-227.
  118. Vortmeyer A.O., Huang S., Lubensky I. Nonislet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004; 89: 1934-1938.
  119. Wamsteker E.J., Gauger R.G., Thompson N.W. EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc 2003; 58: 531-535.
  120. Weber N.S., Venzon D.J., Lin J.T. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 1637-1649.
  121. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954; 16: 363-371.
  122. Wiedenmann B., Jensen R.J., Mignon M. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998; 22: 309-318.
  123. Yang Y., Hua X. In search of tumor suppressing functions of menin. Mol Cell Endocrinol 2007; 265-266: 34-41.
  124. Yim J.H., Siegel B.A., DeBenedetti M.K. Prospective study of the utility of somatostatin-receptor scintigraphy Inherited PET Syndromes/Jensen et al 1837 in the evaluation of patients with multiple endocrine neoplasia type 1. Surgery 1998; 124: 1037-1042.
  125. You Y.N., Thompson G.B., Young W.F. Pancreatoduodenal surgery in patients with multiple endocrine neoplasia type 1: operative outcomes, long-term function, and quality of life. Surgery 2007; 142: 829-836.
  126. Zollinger R.M., Ellison E.H. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142: 709-728.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.